-
Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification
•
A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached the primary objective of identifying a second novel target for neurodegenerative disorders. This achievement was made possible through the use of BridGene’s chemoproteomics platform, which is designed to discover and develop small molecules for undruggable…
